Multidrug resistance protein 4/ ATP binding cassette transporter 4: A new potential therapeutic target for acute myeloid leukemia

Oncotarget

Volumn 5, Issue 19, 2014, Pages 9308-9321

  Copsel, Sabrina ^a,b   Bruzzone, Ariana ^a   May, Maria ^a   Beyrath, Julien ^c   Wargon, Victoria ^a   Cany, Jeannette ^c   Russel, Frans G M ^c   Shayo, Carina ^a   Davio, Carlos ^b  

^a INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Acute myeloid leukemia; Apoptosis; Differentiation; Leukemic stem cells; MRP4 ABCC4

Indexed keywords

ABC TRANSPORTER; ATP BINDING CASSETTE TRANSPORTER 4; CYCLIC AMP; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; PHOSPHODIESTERASE IV; PROBENECID; ROLIPRAM; UNCLASSIFIED DRUG; ABCC4 PROTEIN, HUMAN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MULTIDRUG RESISTANCE PROTEIN; PHOSPHODIESTERASE IV INHIBITOR; SMALL INTERFERING RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOSTASIS; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INDEX; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CYTOLOGY; DISEASE COURSE; DRUG EFFECTS; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIC AMP; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, NUDE; MITOTIC INDEX; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PHOSPHODIESTERASE 4 INHIBITORS; RNA INTERFERENCE; RNA, SMALL INTERFERING; ROLIPRAM; TRANSPLANTATION, HETEROLOGOUS;

EID: 84910084359     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2425     Document Type: Article

References (47)

1. Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Childhood and adolescent lymphoid and myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004; 118-45.
2. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006; 368(9550): 1894-907.
3. Tallman MS, Gilliland DG, Rowe JM. Drug therapy for acute myeloid leukemia. Blood. 2005; 106(4): 1154-63.
4. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004; 6(2): 129-37.
5. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer. 2010; 10(2): 147-56.
6. Tortora G, Tagliaferri P, Clair T, Colamonici O, Neckers LM, Robins RK, Cho-Chung YS. Site-selective cAMP analogs at micromolar concentrations induce growth arrest and differentiation of acute promyelocytic, chronic myelocytic, and acute lymphocytic human leukemia cell lines. Blood. 1988; 71(1): 230-3.
7. Guillemin MC, Raffoux E, Vitoux D, Kogan S, Soilihi H, Lallemand-Breitenbach V, Zhu J, Janin A, Daniel MT, Gourmel B, Degos L, Dombret H, Lanotte M, De The H. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia. J Exp Med. 2002; 196(10): 1373-80.
8. Kim SN, Ahn YH, Kim SG, Park SD, Cho-Chung YS, Hong SH. 8-Cl-cAMP induces cell cycle-specific apoptosis in human cancer cells. Int J Cancer. 2001; 93(1): 33-41.
9. Oevermann L, Scheitz J, Starke K, Kock K, Kiefer T, Dolken G, Niessen J, Greinacher A, Siegmund W, Zygmunt M, Kroemer HK, Jedlitschky G, Ritter CA. Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009; 124(10): 2303-11.
10. Guo Y, Kock K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res. 2009; 15(5): 1762-9.
11. Burger AM. Targeting leukemic stem cells. In: Bagley RG TB, editor. Stem cells and cancer. Massachusetts: Humana Press, Springer Science. p. 263-72.
12. de Grouw EP, Raaijmakers MH, Boezeman JB, van der Reijden BA, van de Locht LT, de Witte TJ, Jansen JH, Raymakers RA. Preferential expression of a high number of ATP binding cassette transporters in both normal and leukemic CD34+CD38-cells. Leukemia. 2006; 20(4): 750-4.
13. Copsel S, Garcia C, Diez F, Vermeulem M, Baldi A, Bianciotti LG, Russel FG, Shayo C, Davio C. Multidrug resistance protein 4 (MRP4/ABCC4) regulates cAMP cellular levels and controls human leukemia cell proliferation and differentiation. J Biol Chem. 2011;286(9):6979-88.
14. Koeffler HP. Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood. 1983; 62(4): 709-21.
15. She M, Niu X, Chen X, Li J, Zhou M, He Y, Le Y, Guo K. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity. Cancer Lett. 2012; 318(2): 173-9.
16. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, Meyerrose T, Rossi R, Grimes B, Rizzieri DA, Luger SM, Phillips GL. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10): 1777-84.
17. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der Meer A, Joosten I, Schaap N, de Witte TM, Dolstra H. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy. PLoS One. 2010; 5(2): e9221.
18. Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen J D, Horvath LG. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate. 2008; 68(13): 1421-9.
19. Montani M, Hermanns T, Muntener M, Wild P, Sulser T, Kristiansen G. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. Virchows Arch. 2013;462(4):437-43.
20. Zhao X, Guo Y, Yue W, Zhang L, Gu M, Wang Y. ABCC4 is required for cell proliferation and tumorigenesis in non-small cell lung cancer. Onco Targets Ther. 2014; 7: 343-51.
21. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, London WB, Marshall GM, Allen JD, Haber M. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther. 2005; 4(4): 547-53.
22. Zhang Z, Wang J, Shen B, Peng C, Zheng M. The ABCC4 gene is a promising target for pancreatic cancer therapy. Gene. 2012; 491(2):194-9.
23. Lian S, Wang Y, Zhou S, Sukthankar M, Neale GA, Downing JR, Schuetz JD. A role of Abcc4/Mrp4 in pediatric acute myeloid leukemia (AML). 10th Annual ABC Genetic Workshop; 2013; Maryland: Blood.
24. Hara Y, Sassi Y, Guibert C, Gambaryan N, Dorfmuller P, Eddahibi S, Lompre A M, Humbert M, Hulot JS. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011; 121(7): 2888-97.
25. Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends Pharmacol Sci. 2008; 29(4): 200-7.
26. Karin M. Signal transduction from the cell surface to the nucleus through the phosphorylation of transcription factors. Curr Opin Cell Biol. 1994; 6(3): 415-24.
27. Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark. 2007; 3(4-5): 245-50.
28. Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci. 2005; 1044: 1-5.
29. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009; 113(16): 3655-65.
30. Lerner A, Epstein PM. Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies. Biochem J. 2006; 393: 21-41.
31. Blagosklonny MV. NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget. 2011;2(12):1352-67.
32. Blagosklonny MV. Do cells need CDK2 and. Bcr-Abl? Cell Death Differ. 2004;11(3):249-51.
33. Kobsar A, Heeg S, Krohne K, Opitz A, Walter U, Bock M, Gambaryan S, Eigenthaler M. Cyclic nucleotide-regulated proliferation and differentiation vary in human hematopoietic progenitor cells derived from healthy persons, tumor patients, and chronic myelocytic leukemia patients. Stem Cells Dev. 2008; 17(1): 81-91.
34. Lanotte M, Hermouet S, Gombaud-Saintonge G, Dobo I. On growth regulation of the rat promyelocytic leukemia (BNML): growth inhibition and eradication of clonogenic cells by cholera toxin. Leuk Res. 1986; 10(11): 1319-26.
35. Steinbach D, Lengemann J, Voigt A, Hermann J, Zintl F, Sauerbrey A. Response to chemotherapy and expression of the genes encoding the multidrug resistance-associated proteins MRP2, MRP3, MRP4, MRP5, and SMRP in childhood acute myeloid leukemia. Clin Cancer Res. 2003; 9(3): 1083-6.
36. Huynh T, Norris MD, Haber M, Henderson MJ. ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Front Oncol. 2012; 2: 178.
37. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002; 296(5567): 550-3.
38. Scherr M, Steinmann D, Eder M. RNA interference (RNAi) in hematology. Ann Hematol. 2004; 83(1): 1-8.
39. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 1998; 77(1): 1-10.
40. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102(11): 1555-77.
41. Wendel V, Vazquez SM, Durante PC, Lemoine AP, Segura ET, Calandra RS, Luthy IA. Prazosin and stress effect on tumoral growth of 7,12-dimethylbenz[A]anthracene-induced rat mammary tumors. Acta Physiol Pharmacol Ther Latinoam. 1996; 46(4): 277-85.
42. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26(4): 239-57.
43. Vanzulli S, Efeyan A, Benavides F, Helguero LA, Peters G, Shen J, Conti CJ, Lanari C, Molinolo A. p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis. 2002; 23(5): 749-58.
44. El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2-and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007; 320(1): 229-235.
45. Montero Girard G, Vanzulli SI, Cerliani JP, Bottino MC, Bolado J, Vela J, Becu-Villalobos D, Benavides F, Gutkind S, Patel V, Molinolo A, Lanari C. Association of estrogen receptor-alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res. 2007; 9(2): R22.
46. van Aubel RA, Smeets PH, Peters JG, Bindels RJ, Russel FG. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol. 2002; 13(3): 595-603.
47. Davio C, Cricco GP, Bergoc RM, Rivera ES. H1 and H2 histamine receptors in N-nitroso-N-methylurea (NMU)-induced carcinomas with atypical coupling to signal transducersBiochem Pharmacol. 1995; 50(1), 91-96.